The potential cures inside you: fighting cancer with the immune system
Being at the forefront of immuno-oncology research means more hope for patients.
Oct 22, 2015
By Alessandro Riva, M.D., Global Head of Oncology Development and Medical Affairs, Novartis Oncology
At Novartis, we aspire to be a leader in next-generation immuno-oncology. Our portfolio of investigational targeted therapies positions us well to have the opportunity to further advance the science of immuno-oncology as growing evidence supports the rationale for a combination approach to immuno-oncology treatment for best outcomes, including the combination immuno-oncology and targeted therapy approach.
Advancements in immuno-oncology are happening at a lightning pace. The earliest immuno-oncology agents created a great deal of enthusiasm for this new science, but we believe that there is still much more progress to be made. We at Novartis want to grow the field around immuno-oncology and see promise in the next generation of immuno-oncology agents to be able to expand our efforts to help even more patients with even better outcomes.
We have made significant commitments in immuno-oncology recently, as I discussed earlier this year around important oncology meetings here, and plan to continue to do so. Our diverse investigational immuno-oncology portfolio now includes:
First generation checkpoint inhibitors (PD-1 mAb, PD-L1 mAb)
Second generation checkpoint inhibitors (LAG-3 mAb, CSF-1 mAb, TIM-3 mAb)
PBF-509, an adenosine receptor antagonist (collaboration with Palobiofarma; read more here)
STING agonist (collaboration with Aduro Biotech; read more here)
TGF-beta antibodies (collaboration with XOMA; read more here)
Image: Christian Lee/GNF Structural Biology Team
Researchers at the Genomics Institute of the Novartis Research Foundation study what happens at the molecular level to STING when a natural signal called cGAMP (shown between the green and blue) binds and activates it.
We hope to continue to grow our clinical collaborations, including with other pharmaceutical companies that will allow us to look at a greater number of potential combination treatment strategy approaches. As well, we plan to leverage our leadership in targeted therapies and build a strong immuno-oncology platform.
Using our knowledge and the compounds within our own pipeline gives us the opportunity to study various combination treatment approaches not only with immuno-oncology agents, but also targeted therapies. We currently have four key assets in Phase I studies in solid tumors, including a first generation and two second generation checkpoint inhibitors, and an anti-CSF1.
Cancer research has never been more exciting. Our leadership in targeted therapies and growing capability in immuno-oncology continues to put us at the forefront of science to bring forth new options and hope for cancer patients around the world.
Click here to read more about Novartis and our commitment to immuno-oncology research.